ISA Pharmaceuticals Appoints Ronald Loggers as Chief Executive Officer
Leiden, The Netherlands, July 07, 2014 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that the Company has hired Ronald Loggers, the former Chairman of ISA´s Supervisory Board, as Chief Executive Officer.
Previously, Ronald Loggers, M.Sc., MBA, was Managing Director of Multifund B.V., a family-owned investment firm and one of ISA’s major investors. Until June 2013, he served as the Chairman of the Supervisory Board and subsequently assumed the role of Acting CEO of ISA Pharmaceuticals.
From 1998 to 2005, Ronald Loggers worked for private equity firm HAL Investments. During that period, he served on several boards such as the Supervisory Board of Schreiner Luchtvaart Groep B.V., and as Managing Director for the production and logistics facilities of optical retailer Pearle Benelux. From 1993 until 1998, he worked for McKinsey & Company. From 1991 to 1992, he was a manager at the quality control laboratories of Fokker Aircraft’s Ypenburg plant. Ronald Loggers holds an MBA from INSEAD and an M.Sc. in Chemical Engineering from Delft University of Technology.
“We are very pleased that Ronald Loggers, whom we hold in high esteem and know well from his role as ISA’s Chairman, has decided to lead ISA permanently in an executive role,” said Pieter van der Meijden, Chairman of ISA´s Supervisory Board. “He brings outstanding leadership and management experience from various industries, which will be very important for the further corporate development of ISA.”
“With its SLP immunotherapeutics and the AMPLIVANT technology, ISA has a leading edge in cancer immunotherapy,” added Ronald Loggers. “The results accomplished to date are very impressive and I am committed to building ISA into a successful immunotherapy company over the coming years. Together, we will advance ISA’s product portfolio for the benefit of patients suffering from cancer and viral infections.”
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections. The company has built a proprietary vaccine platform based on the Synthetic Long Peptide (SLP®) and AMPLIVANT® technologies, which enable the generation of safe and effective vaccines with a known mechanism of action. SLP® vaccines are broadly applicable to multiple targets and ideally suited as monotherapy or as essential components in combination with conventional cancer treatments or novel immunomodulators. SLP® vaccine therapies are capable of fully harnessing and directing the body‘s own defense towards fighting the disease.
ISA101, an SLP® vaccine targeting human papillomavirus (HPV)-induced diseases, is currently in clinical development in cervical cancer and anal intraepithelial neoplasia (AIN). Clinical proof-of-concept has been established with ISA101 in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV.
The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit www.isa-pharma.com
AMPLIVANT® is a registered trademark in Europe.
Contact & Media Inquiries:
Dr. Ludger Wess , Ines-Regina Buth
Tel. +49 40 88 16 59 64, Tel. +49 30 23 63 27 68